Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials

Richard Shikiar, Brian W Bresnahan, Stephen P Stone, Christine Thompson, John Koo, Dennis A Revicki, Richard Shikiar, Brian W Bresnahan, Stephen P Stone, Christine Thompson, John Koo, Dennis A Revicki

Abstract

Background: Two Phase III randomized controlled clinical trials were conducted to assess the efficacy, safety, and tolerability of weekly subcutaneous administration of efalizumab for the treatment of psoriasis. Patient reported measures of psoriasis-related functionality and health-related quality of life and of psoriasis-related symptom assessments were included as part of the trials.

Objective: To assess the reliability, validity, and responsiveness of the patient reported outcome measures that were used in the trials - the Dermatology Life Quality Index (DLQI), the Psoriasis Symptom Assessment (PSA) Scale, and two itch measures, a Visual Analog Scale (VAS) and the National Psoriasis Foundation (NPF) itch measure.

Methods: Subjects aged 18 to 70 years with moderate to severe psoriasis for at least 6 months were recruited into the two clinical trials (n = 1095). Internal consistency reliability was evaluated for all patient reported outcomes at baseline and at 12 weeks. Construct validity was evaluated by relations among the different patient reported outcomes and between the patient reported outcomes and the clinical assessments (Psoriasis Area and Severity Index; Overall Lesion Severity Scale; Physician's Global Assessment of Change) assessed at baseline and at 12 weeks, as was the change over the course of the 12 week portion of the trial.

Results: Internal consistency reliability ranged from 0.86 to 0.95 for the patient reported outcome measures. The patient reported outcome measures were all shown to have significant construct validity with respect to each other and with respect to the clinical assessments. The four measures also demonstrated significant responsiveness to change in underlying clinical status of the patients over the course of the trial, as measured by the independently assessed clinical outcomes.

Conclusions: The DLQI, the PSA, VAS, and the NPF are considered useful tools for the measurement of dermatology-related limitations of functional ability and the frequency, severity and impact of psoriasis symptoms on patients' lives and psoriasis-related quality of life.

References

    1. de Arruda LH, De Moraes AP. The impact of psoriasis on quality of life. Br J Dermatol. 2001;144:33–6.
    1. Finlay AY. Quality of life assessments in dermatology. Seminars Cutan Med Surg. 1998;17:291–6.
    1. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280–4.
    1. Rapp SR, Cottrell CA, Lary MR. Social coping strategies associated with quality of life decrements among psoriasis patients. Br J Dermatol. 2001;145:610–6. doi: 10.1046/j.1365-2133.2001.04444.x.
    1. Wahl A. The impact of psoriasis on psychosocial life domains. A review. Scand J Caring Sci. 1997;11:243–9.
    1. Wahl A, Loge JH, Wiklund I, Hanestad BR. The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. J Am Acad Dermatol. 2000;43:803–8. doi: 10.1067/mjd.2000.107501.
    1. Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol. 2002;47:512–8. doi: 10.1067/mjd.2002.122755.
    1. Gupta MA, Gupta AK. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol. 1995;75:240–3.
    1. Gupta MA, Gupta AK. Psoriasis and sex: a study of moderately to severely affected patients. Int J Dermatol. 1997;36:259–62. doi: 10.1046/j.1365-4362.1997.00032.x.
    1. Javitz HS, Ward MM, Farber E, ail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002;46:850–60. doi: 10.1067/mjd.2002.119669.
    1. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995;132:236–44.
    1. Kirby B, Richards HL, Woo P, Hindle E, Main CJ, Griffiths CE. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Acad Am Dermatol. 2001;45:72–6. doi: 10.1067/mjd.2001.114592.
    1. Chren MM, Lasek J, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Investig Dermatol. 1996;107:707–13.
    1. Chren MM, Lasek J, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133:1440–3.
    1. Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5:105–10.
    1. Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of Sickness Impact Profile and Psoriasis Disability Index in psoriasis. Br J Dermatol. 1990;123:751–6.
    1. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–6.
    1. National Psoriasis Foundation New method being developed for assessing psoriasis. NPF Forum. 1999;5
    1. Revicki DA, Osoba D, Fairclough D, Barofsky I, Berzon R, Leidy NK, Rothman M. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res. 2000;9:887–900. doi: 10.1023/A:1008996223999.
    1. Koo JY, Leonardi C, Papp KA, Tyring S, Glazer S, Harvey D, McCall CO, Stone SP, Abuabara F, Hamlin R, Korman N, Wang X, Garovoy M, Walicke P, Lebwohl M. Subcutaneous Efalizumab (anti-CD11a) is Safe and Well Tolerated in the Treatment of Moderate to Severe Plaque Psoriasis: Pooled Results of 2 Phase III Clinical Trials, poster presentation, 60th Annual Meeting of the American Academy of Dermatology. 2002.
    1. Fredriksson T, Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica. 1978;157:238–44.
    1. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999;141:185–91. doi: 10.1046/j.1365-2133.1999.02963.x.
    1. Hays RD, Anderson RT, Revicki DA. Assessing reliability and validity of measurement in clinical trials. In: Staquet M, Hays RD, Fayers P, editor. Quality of Life Assessment in Clinical Trials: Methods and Practice. New York: Oxford University Press; 1998.
    1. Nunnally J. Psychometric Theory. Second. New York: McGraw-Hill; 1978.
    1. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–34.
    1. Badia X, Mascaro JM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. Br J Dermatol. 1999;141:698–02. doi: 10.1046/j.1365-2133.1999.03112.x.
    1. Zacharie R, Zachariae C, Ibsen H, Mortensen JT, Wulf HC. Dermatology life quality index: data from Danish inpatients and outpatients. Acta Dermatol Venereol. 2000;80:272–6. doi: 10.1080/000155500750012153.
    1. Nichol MB, Margolies JE, Lippa E, Rowe M, Quell J. The application of multiple quality-of-life measurements in individuals with mild-to-moderate psoriasis. Pharmacoeconomics. 1996;10:644–53.
    1. Ellis CN, Mordin MM, Adler EY. Effects of Alefacept on Health-Related Quality of Life in Patients with Psoriasis: Results from a Randomized, Placebo-Controlled Phase II Trial. Am J Clin Dermatol. 2003;4:131–9.
    1. Bagel J, Garland WT, Breneman D, Holick M, Littlejohn TW, Crosby D, Faust H, Fivenson D, Nichols J. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. J Am Acad Dermatol. 1998;38:938–44.
    1. Touw CR, Hakkaart-Van Roijen L, Verboom P, Paul C, Rutten FF, Finlay AY. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol. 2001;144:967–72. doi: 10.1046/j.1365-2133.2001.04183.x.
    1. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE. Quality of life measures in psoriasis: a critical appraisal of their quality. J Clin Pharm Ther. 1998;23:391–8. doi: 10.1046/j.1365-2710.1998.00181.x.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться